ROCKVILLE, Md., May 12 /PRNewswire-FirstCall/ -- Stem cell company Neuralstem, Inc. (Amex: CUR) responded today to the two new patent infringement suits filed against it Friday by StemCells, Inc., saying that it believes them, and the earlier claims by StemCells, Inc. against the company, to be baseless.
"As we alleged in the counterclaim to their lawsuit, which we filed in October, 2006, StemCells, Inc. has engaged in a pattern of harassment and anti-competitive behavior," said Neuralstem CEO and President, Richard Garr. "This is what we have come to expect from StemCells, Inc. and we believe these new suits are entirely consistent with its past strategy."
"The other interesting point of today's press release is that StemCells, Inc., is now backing off of its promise, made publicly in a press release not long ago, to expeditiously re-open its original infringement suit against us," Garr continued. "In fact, Neuralstem moved to re-open that suit, so that it could move for summary judgment based upon the Patent Office's recent actions. To us, it sounds like StemCells, Inc. is now trying to make an excuse for arguing against re-opening that case. We are not surprised. As we said earlier, we believe that actions of the Patent Office have destroyed the basis for those infringement assertions against us."
Neuralstem's patented technology enables, for the first time, the
ability to produce neural stem cells of the human brain and spinal cord in
commercial quantities, and the ability to control the differentiation of
these cells into mature, physi
|SOURCE Neuralstem, Inc.|
Copyright©2008 PR Newswire.
All rights reserved